Medical Policy Non-invasive Tests for Hepatic Fibrosis
|
|
- Junior Harvey
- 6 years ago
- Views:
Transcription
1 Medical Policy Non-invasive Tests for Hepatic Fibrosis Subject: Non-invasive Tests for Hepatic Fibrosis Background: Accurately diagnosing liver fibrosis and inflammatory activity are the most important factors for determining the stage of the disease, assessing the patient's prognosis, and predicting treatment responses. Liver biopsy has been the gold standard test for assessing hepatic fibrosis. Recently, non-invasive tests have been developed as alternatives to biopsy. Policy and Coverage Criteria: Harvard Pilgrim Health Care (HPHC) considers the following non-invasive tests as reasonable and medically necessary to assess and evaluate the degree of liver fibrosis and cirrhosis in members with chronic liver disease (e.g. chronic Hepatitis C Virus (HCV) infection): Imaging tests o Ultrasound-based Transient elastography (e.g. FibroScan) Serum marker tests: Only one of the below tests is covered only single time (once) per member o FibroTest-ActiTest; o HCV-FibroSure; Exclusions: Harvard Pilgrim Health Care (HPHC) considers non-invasive fibrosis test as not medically necessary for all other indications. In addition, HPHC does not cover monitoring of fibrosis or cirrhosis in individuals with chronic liver disease (e.g. chronic Hepatitis C Virus (HCV) infection) for the following: Imaging tests o Ultrasound-based Transient elastography (e.g. FibroScan) Serum marker tests: Only one of the below tests is covered for only single time per member o FibroTest-ActiTest; o HCV-FibroSure; In addition, Harvard Pilgrim Health Care (HPHC) considers the following non-invasive fibrosis tests as not medically necessary in the diagnosis (evaluation) and monitoring of individuals with hepatitis C or other chronic liver disease. There is insufficient evidence in clinical literature to support their use (this list is not all-inclusive): Imaging tests o Acoustic Radiation Force Impulse (ARFI) o Magnetic Resonance Elastography (MRE) o Real time Shear Wave Elastography (SWE) Serum marker tests o FibroMAX o FibroSpect o HepaScore o FibroMeter o NASH FibroSure Non-invasive Tests for Hepatic Fibrosis Page 1 of 6
2 Supporting Information: Transient elastography (TE) involves the ultrasonographic analysis of wave propagation and tissue deformation in patients suspected of or known to have chronic liver disease. TE is based on the principle that fibrosis changes the elasticity and viscosity of tissue. By assessing the propagation of acoustic waves through liver tissue, the extent of fibrosis can be measured. FibroScan uses vibration-controlled TE to noninvasively measure liver stiffness. Serologic marker testing for hepatic fibrosis involves indirect and direct markers. Indirect markers reflect alterations in hepatic function, but do not directly reflect extracellular matrix metabolism. Examples include the platelet count, coagulation studies, and liver aminotransferases. Direct markers of fibrosis reflect extracellular matrix turnover. Examples include procollagen types I and III, hyaluronic acid, and tissue inhibitor of metalloproteinase. Current clinical evidence supports the use of TE for staging of hepatic fibrosis related to liver disease. A number of systematic reviews and meta-analyses reported diagnostic accuracy of TE for fibrosis and cirrhosis assessment. There is limited evidence to support the use of serum marker tests to accurately stage liver fibrosis. Fernandez et al (2015) conducted a retrospective study including 135 patients with alcoholic liver disease who underwent liver biopsy. Fibroscan, Fibrotest, FIB-4, APRI, and Forns scores were tested in all patients. Diagnostic accuracy of Fibroscan was 0.89 for the diagnosis of advanced fibrosis and 0.93 for the diagnosis of cirrhosis. Fibroscan performed better than all other tests. The authors concluded that Fibroscan is currently the most reliable noninvasive method for the diagnosis of advanced liver fibrosis and cirrhosis in alcoholic liver disease. Seo et al (2015) investigated the diagnostic performance of liver stiffness (LS) measurement using TE in Korean patients with chronic hepatitis B and C (CHB and CHC). 916 patients who underwent liver biopsy and TE were analyzed. Aspartate aminotransferase (AST)-to-platelet ratio indexes (APRI) were calculated. TE was significantly superior to APRI in CHB patients and was significantly superior for predicting F3 stage, whereas it was similar for predicting F2 and F4 stage in CHC patients. The authors concluded that TE can accurately assess the degree of liver fibrosis and was superior to APRI for predicting each fibrosis stage in Korean patients with CVH. Gobel et al (2015) investigated the diagnostic significance of TE in a daily routine clinical setting in comparison to clinical signs, laboratory parameters and US in 291 patients with chronic liver disease who underwent liver biopsy. Sensitivity of TE for the detection of liver cirrhosis was 90.4% compared to 80.1% for US, 58% for platelet count and 45.1% for cutaneous liver signs. Combining TE with US increased sensitivity to 96.1%. The authors concluded that TE is superior to routine diagnostic tests allowing detection of liver cirrhosis in additional 10-16% of patients with chronic liver disease that would have been missed. Jia et al (2015) compared liver stiffness results using TE to histological staging and serum fibrosis markers in 469 patients with CHB. The authors found that TE is a reliable noninvasive technique to predict significant liver fibrosis in Chinese patients with CHB and is superior to current biomarker panels. It was also found that enhanced inflammatory activity can lead to elevated stiffness values unrelated to histological fibrosis stage. Castera et al (2014) compared the performance of TE, Fibrotest, APRI, and two algorithms combining TE and Fibrotest or APRI and Fibrotest in 116 HIV/HCV coinfected patients. For a fibrosis score of greater than or equal to 2, both TE and Fibrotest had a significantly better diagnostic performance than APRI. For a fibrosis score of 4, TE had significantly better performance than Fibrotest. The authors concluded that in HIV/HCV-coinfected patients, TE and Fibrotest have a similar diagnostic accuracy for significant fibrosis. For patients with cirrhosis, TE has the best accuracy. The combination algorithms did not improve diagnostic performance. Aykut et al (2014) compared the diagnostic performance of FibroMeter, NFSA, and TE for the detection of liver fibrosis in 88 patients with biopsy-proven NAFLD. The sensitivities/specificities for the FibroMeter score, NFSA, and TE for the diagnosis of significant fibrosis (F2 + F3 + F4 fibrosis) were 38.6%/86.4%, 52.3%/88.6%, and Non-invasive Tests for Hepatic Fibrosis Page 2 of 6
3 75.0%/93.2%, respectively. The areas under the receiver operating characteristic curves of TE were significantly higher than those of both the FibroMeter score and NFSA. No differences were found between the FibroMeter score and NFSA for the detection of significant and severe fibrosis, although the diagnostic performance of the FibroMeter score was higher than that of the NFSA score for cirrhosis. The authors concluded that TE showed the best diagnostic performance for the noninvasive assessment of liver fibrosis in NAFLD patients. Abd El Rihim et al. (2013) found Fibroscan and APRI to be clinically useful tests for detecting cirrhosis. The authors performed a systematic review and meta-analysis of diagnostic accuracy studies comparing Fibroscan and APRI with liver biopsy for hepatic fibrosis. 23 studies for fibroscan and 20 studies for APRI in full publication were identified. For patients with stage IV fibrosis (cirrhosis), the pooled estimates for sensitivity of fibroscan were 83.4% and specificity 92.4%. For patients with stage IV fibrosis (cirrhosis), the pooled estimates for sensitivity of APRI at cutoff point of 1.5 were 66.5% and specificity 71.7%. Adebajo et al (2012) performed a systematic review and meta-analysis of studies comparing US-based TE to live biopsy for the detection of hepatic fibrosis due to recurrent HCV infection after liver transplantation (LT). Six fully published studies were identified for analysis. Among these studies, the pooled estimates were 83% for sensitivity, 83% for specificity, 4.95 for the positive likelihood ratio, 0.17 for the negative likelihood ratio, and 30.5 for the diagnostic odds ratio. For the 5 studies that assessed cirrhosis, the pooled estimates were 98% for sensitivity, 84% for specificity, 7 for the positive likelihood ratio, 0.06 for the negative likelihood ratio, and 130 for the diagnostic odds ratio. A diagnostic threshold the authors concluded that US-based TE has excellent diagnostic accuracy for identifying cirrhosis due to a recurrent HCV infection after LT. The detection of significant fibrosis is more accurate for these patients versus patients whose native liver is chronically infected with HCV. UptoDate analysis of various studies have found Hepascore to be a useful to test for predicting fibrosis in HCV. UptoDate also states that the panels of direct markers of hepatic fibrosis include FibroSpect II, Serum Hyaluronic Acid level with serum AST and Albumin level (SHASTA), and the European Liver Fibrosis panel (ELF). However, none of this are yet part of standard clinical practice. There is a variability on the accuracy of the panels depending on the cut-offs used. For example, in a study on 1021 patients with chronic liver disease ELF was shown to have sensitivity of 87 to 90 percent and a specificity of 41 to 51 percent for diagnosing moderate or severe fibrosis using a threshold score of 0.102, whereas the specificity increased to 95 percent using a threshold score of UptoDate report also states that serum marker tests have their own limitations as they are not specific for liver and their levels are affected by the hepatic clearance rate. They are typically surrogates of liver fibrosis instead of inflammation. Moreover, they typically reflect matrix turnover and hence tend to be more elevated with high inflammatory activity and lower with no inflammation. According to technology assessment report by ECRI a large body of studies show that Acoustic Radiation Force Impulse (ARFI) is non-inferior to serum markers and transient elastography (TE) for assessing liver fibrosis but is less accurate than magnetic resonance elastography (MRE) or two-dimensional shear-wave elastography (2-D SWE); however, there is insufficient evidence to assess ARFI's effect on patient outcomes and healthcare costs. Hayes has assigned a rating of C for use of MRE for detecting and staging liver fibrosis in adults with known or suspected liver disease despite high reported AUC due to lack of uniformity in standardized cut-off values for staging of liver fibrosis across the literature. According to Hayes lack of standardization of cut-off for staging limits the generalized application of technology in clinical practice. UptoDate also states that though MRE is comparable to ultrasound-based transient elastography in terms of accuracy, it can be much more expensive than ultrasound. Non-invasive Tests for Hepatic Fibrosis Page 3 of 6
4 Fibroscan (Echosens SA, Paris, France, available in the US through Sandhill Scientific, Highlands Ranch, CO) received FDA 510(k) approval on April 5, Fibroscan is indicated for noninvasive measurement of shearwave speed at 50 Hz in the liver. The FibroScan device uses transient elastography for the non-invasive measurement of liver shear wave speed. A mechanical vibrator produces low-amplitude elastic waves that travel through the skin and intercostal space into the liver. European Association for the Study of the Liver states the 2D-SWE is a promising technique that is currently under investigation. It seems to be at least equivalent to TE and point shear wave elastography (pswe)/arfi for non-invasive staging of liver fibrosis in viral hepatitis (B1-Moderate quality of evidence: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate, strong recommendation). Comparison between MR elastography and TE has provided conflicting results. Further data are needed (A1-Hugh quality of evidence: Further research is very unlikely to change our confidence in the estimate of effect, strong recommendation). Coding: Codes are listed below for informational purposes only, and do not guarantee member coverage or provider reimbursement. The list may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible. CPT Code Description Unlisted multianalyte assay with algorithmic analysis [when specified as serum markers for liver fibrosis, including FIBROSpect II, Hepascore combination tests] Immunoassay, analyte, quantitative; not otherwise specified [If billed for FIBROSpect or HCV FIBROSURE FIbroMAX, FibroTest, ActiTest, HepaScore] Nephelometry, each analyte not elsewhere specified [If billed for FIBROspect or HCV FIBROSUREFibroMAX, FibroTest, ActiTest, HepaScore] Liver elastography, mechanically induced shear wave (eg, vibration), without imaging, with interpretation and report Billing Guidelines: Member s medical records must document that services are medically necessary for the care provided. Harvard Pilgrim Health Care maintains the right to audit the services provided to our members, regardless of the participation status of the provider. All documentation must be available to HPHC upon request. Failure to produce the requested information may result in denial or retraction of payment. References: 1. Abd El Rihim AY, Omar AF, Fathalah W, et al. Role of fibroscan and APRI in detection of liver fibrosis: a systematic review and meta-analysis. Arab J Gastroenterol. 2013;14(2): Acoustic Radiation Force Impulse for Evaluating Liver Fibrosis. ECRI.org/login [via subscription only]. Published January 9, Updated December 28, Accessed February 15, Adebajo CO, Talwalker JA, Poterucha JJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012;18(3): Non-invasive Tests for Hepatic Fibrosis Page 4 of 6
5 4. Afdhal NH, Bacon BR, Patel K, et al. Diagnostic accuracy of liver stiffness (FibroScan(registered trademark)) in patients with chronic viral hepatitis: Results of a large USA cohort. Hepatology. 2013;58(4 Suppl. 1):278A- 279A. 5. Aykut UE, Akyuz U, Yesil A, et al. A comparison of FibroMeter NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol. 2014;49(11): Bota S, Herkner H, Sporea I, et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int. 2013;33(8): Castera L, Winnock M, Pambrun E, et al. Comparison of transient elastography (Fibroscan), Fibrotest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Med. 2014;15(1): Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142(6): Curry MP, Afdhal NH. Noninvasive assessment of hepatic fibrosis: Overview of serologic and radiographic tests. UpToDate.com/login [via subscription only]. Published Updated January Accessed February 15, Dietrich CF. Noninvasive assessment of hepatic fibrosis: Utrasound-based elastography. UpToDate.com/login [via subscription only]. Published European Association for the Study of the Liver (EASL), Associacion Latinoamericana para el Estudio del Higado (ALEH). EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology.2015;63: Fernandez M, Trepo E, Degre D, et al. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease. Eur J Gastroenterol Hepatol Ferraioli G, Tinelli C, Dal BB, et al. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology. 2012;56(6): FibroScan (EchoSens) Transient Elastography for Determining Optimal Candidates for Hepatitis C Pharmacotherapy. Custom Product Brief. ECRI.org/login [via subscription only]. Published October 9, FibroSpect II (Prometheus Laboratories, Inc.) Serum Markers Panel for Evaluating Hepatitis C related Liver Fibrosis. Custom Product Briefs Guidance. ECRI.org/login [via subscription only]. Published April 27, Updated December 28, Accessed February 15, FIBROSpect II Test (Prometheus Laboratories Inc.) for Diagnosis of Liver Fibrosis in Patients with Hepatitis C. Health Technology Brief. Hayesinc.com/login [via subscription only]. Published March 26, Accessed February 15, Fransen van de PD, Blom R, Van SH, et al. Impact of Fibroscan on management of chronic viral hepatitis in clinical practice. Ann Hepatol. 2011;10(4): Gobel T, Schadewaldt-Tummers J, Greiner L, et al. Transient elastography improves detection of liver cirrhosis compared to routine screening tests. World J Gastroenterol. 2015;21(3): Horowitz JM, Kamel IR, Arif-Tiwari H, et al. ACR Appropriateness Criteria chronic liver disease. American College of Radiology (ACR). Published Accessed February 15, Jia J, Hou J, Ding H, et al. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30(4): Lim JK, Flamm SL, Singh S, et al. American Gastroenterological Association Institute guideline on the role of elastography in the evaluation of liver fibrosis. Gastroenterology. 2017;152(6): Magnetic Resonance Elastography for Detecting and Staging Liver Fibrosis. Medical Technology Directory. Hayesinc.com/login [via subscription only]. Published January 21, Updated January 10, Accessed February 15, Non-invasive Tests for Hepatic Fibrosis Page 5 of 6
6 23. Pavlov CS, Casazza G, Nikolova D, et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database of Systematic Reviews. Published January 22, Accessed February 15, Seo YS, Kim MY, Kim SU, et al. Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. Liver Int Sharma P, Dhawan S, Bansal R, et al. The usefulness of transient elastography by FibroScan for the evaluation of liver fibrosis. Indian J Gastroenterol Tsochatzis EA, Crossan C, Longworth L, et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology. 2014;60(3): Ultrasound Transient Elastography for Detecting Hepatic Fibrosis in patients with Hepatitis C. Medical Technology Directory. Hayesinc.com/login [via subscription only]. Published December 9, Updated November 20, Accessed February 15, Summary of Changes: Date Change 4/18 Updated references and background; criteria revised; CPT and ICD-10 code analysis by external reviewer done. No coding changes made. Approved by Medical Policy Review Committee: 4/24/2018 Reviewed/Revised: 5/16, 4/18 Initiated: n/a Non-invasive Tests for Hepatic Fibrosis Page 6 of 6
Ultrasound Transient Elastography for Liver Fibrosis
Ultrasound Transient Elastography for Liver Fibrosis Protocol: RAD042 Effective Date: June 1, 2018 Table of Contents Page COMMERCIAL, MEDICARE & MEDICAID COVERAGE RATIONALE... 1 DESCRIPTION OF SERVICES...
More informationNONINVASIVE TECHNIQUES FOR EVALUATION AND MONITORING OF CHRONIC LIVER DISEASE
LIVER DISEASE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationMP Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease
Medical Policy BCBSA Ref. Policy: 2.04.41 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 9.01.502 Experimental / Investigational Services DISCLAIMER Our medical policies
More informationNoninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease
Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Policy Number: 2.04.41 Last Review: 2/2019 Origination: 2/2017 Next Review: 2/2020 Policy Blue Cross and
More informationINHSU th International Symposium on Hepatitis Care In Substance Users
INHSU 2015 4 th International Symposium on Hepatitis Care In Substance Users Sydney, 7 October 2015 Non-invasive liver fibrosis assessment: Opportunities for enhanced liver disease assessment and treatment
More informationNew Tools for Assessing Disease Sererity, progression and regression in HBV and HCV
New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV Jidong Jia, MD, PhD Beijing Friendship Hospital, Capital Medical University 2016-3-14 Disclosure Consultation for Abbvie
More informationNoninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease
Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Policy Number: 2.04.41 Last Review: 2/2018 Origination: 2/2017 Next Review: 2/2019 Policy Blue Cross and
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Noninvasive Techniques for the Evaluation and Monitoring of Page 1 of 38 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Noninvasive Techniques for the Evaluation
More informationClinical Policy Title: Liver elastography
Clinical Policy Title: Liver elastography Clinical Policy Number: CCP.1118 Effective Date: October 1, 2014 Initial Review Date: June 18, 2014 Most Recent Review Date: August 7, 2018 Next Review Date: August
More informationNational Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Noninvasive Techniques for the Evaluation and Page 1 of 34 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Noninvasive Techniques for the Evaluation and Professional
More informationThe role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases
RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment
More informationClinical Policy Title: Noninvasive assessment of hepatic fibrosis
Clinical Policy Title: Noninvasive assessment of hepatic fibrosis Clinical Policy Number: 08.01.03 Effective Date: Oct. 1, 2014 Initial Review Date: June 18, 2014 Most Recent Review Date: August 17, 2017
More informationLiver 102: Injury and Healing
Liver 102: Injury and Healing Dawn Pease, MSN, RN, ANP-BC Brackenridge Specialty Clinics University Medical Center Brackenridge Austin, TX Seton Healthcare Family Liver 102 Outline Biochemical patterns
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationNon-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology
Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Disclosure Patricia Slev has no relevant financial relationships to disclose. 2 Chronic Liver Disease
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationInvasive. Sampling error. Interobserver variability. Nondynamic evaluation of
How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,
More informationHepatology For The Nonhepatologist
Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able
More informationNONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH
NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH Bachir Taouli, MD Director of Body MRI and Cancer Imaging Program Department of Radiology / Translational and Molecular Imaging Institute
More informationOriginal papers Med Ultrason 2013, Vol. 15, no. 4,
Original papers Med Ultrason 2013, Vol. 15, no. 4, 268-272 DOI: How many measurements are needed for liver stiffness assessment by 2D-Shear Wave Elastography (2D-SWE) and which value should be used: the
More informationPROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO
PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO A. Giorgio Direttore del servizio di Ecografia Interventistica Istituto Clinico S.Rita -IRCCS -Atripalda (Avellino)
More informationBio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis
AASLD 2015 /FibroSure Scientific Publications Section 1 - compared to APRI, FIB-4 and transient elastography Houot 2015, TE, FIB-4, APRI Meta-analysis is superior to TE by Fibroscan, APRI and Fib-4 using
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationLiver elastography ultrasound cpt code
Liver elastography ultrasound cpt code In a multi-center study, Barbero-Villares et al (2012) evaluated the presence of significant liver fibrosis by transient elastography (FibroScan) in inflammatory.
More informationPage: 1 of 19. Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease
and Monitoring of Patients with Chronic Liver Page: 1 of 19 Last Review Status/Date: March 2015 and Monitoring of Patients with Chronic Liver Description Options for noninvasive monitoring of liver fibrosis
More informationResearch Elastography: Liver
Research Elastography: Liver Giovanna Ferraioli EFSUMB Ultrasound Learning Center Ultrasound Unit - Infectious Diseases Dept. Fondazione IRCCS Policlinico S. Matteo Medical School University of Pavia,
More informationTransient elastography the state of the art
Transient elastography the state of the art Laurent CASTERA, MD PhD Department of Hepatology, Hôpital Beaujon, Clichy Université Paris-7, France White Nights of Hepatology, St Petersburg, Russia, june
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationNHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.
Advice Statement 010-18 July 2018 Advice Statement What is the most accurate and cost-effective direct test (ELF test, hyaluronic acid, P3NP, Fibroscan or ARFI elastography) for detecting and staging liver
More informationDATE: 22 June 2015 CONTEXT AND POLICY ISSUES
TITLE: Non-Invasive Methods for Diagnosis and Monitoring of Liver Fibrosis in Patients with Chronic Hepatitis B and C: A Review of Diagnostic Accuracy, Clinical Effectiveness, Cost-Effectiveness and Guidelines
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationTransient elastography in chronic viral liver diseases
4 th AISF POST-MEETING COURSE Roma, 26 Febbraio 2011 Transient elastography in chronic viral liver diseases CRISTINA RIGAMONTI, M.D., Ph.D. Transient elastography (TE): a rapid, non-invasive technique
More informationBio Predictive. FibroTest Scientific Publications. Ratziu 2016 FibroMax NASH. Friedman 2016 FibroTest NASH EASL Key Publications for 2017
EASL 2017 Scientific Publications Ratziu 2016 NASH Friedman 2016 NASH SteatoTest and sensitive markers of improvement in NASH trial using Elafibranor Elafibranor, an agonist of the peroxisome proliferator
More informationHEP DART 2017, Kona, Hawaii
HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George
More informationUltrasound elastography in abdominal imaging
Ultrasound elastography in abdominal imaging Olivier ucidarme Pitié Salpêtrière - UPMC Paris France Ultraschall Med. 013 Apr;34():169-84 Ultraschall Med. 013 Jun;34(3):38-53. US elastography Ultraschall
More informationPretreatment Evaluation
Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University
More informationClinical Policy Title: Serum biomarkers for liver fibrosis in chronic hepatitis
Clinical Policy Title: Serum biomarkers for liver fibrosis in chronic hepatitis Clinical Policy Number: 01.01.01 Effective Date: June 1, 2014 Initial Review Date: December 18, 2013 Most Recent Review Date:
More informationIn Search of New Biomarkers for Nonalcoholic Fatty Liver Disease
REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationHepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFaculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014
Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationNational Horizon Scanning Centre. Transient elastography (FibroScan) for evaluating liver fibrosis. April 2008
Transient elastography (FibroScan) for evaluating liver fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationMultianalyte assays with algorithmic analyses are considered investigational for the diagnosis or monitoring of patients with chronic liver disease.
2.04.41 Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date September
More informationClinical Policy Title: Serum biomarkers for liver fibrosis in chronic hepatitis
Clinical Policy Title: Serum biomarkers for liver fibrosis in chronic hepatitis Clinical Policy Number: 01.01.01 Effective Date: June 1, 2014 Initial Review Date: December 18, 2013 Most Recent Review Date:
More informationMR Elastography of Liver
MR Elastography of Liver Sudhakar K. Venkatesh, MD, FRCR Professor of Radiology Mayo Clinic College of Medicine Consultant, Abdominal Division Radiology, Mayo Clinic Rochester, MN, USA 19 th May 2018 2018
More informationPretreatment Evaluation
Pretreatment Evaluation Objective At the end of this lecture, the learner will be able to: Outline the appropriate evaluation of a person infected with HCV in order to assess the benefits and risks of
More informationIn response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network
Evidence Note Number 82 July 2018 In response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network What is the most accurate and cost-effective direct test (ELF test, hyaluronic
More informationSection: Laboratory Last Reviewed Date: June Policy No: 47 Effective Date: August 1, 2013
Medical Policy Manual Topic: Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Date of Origin: June 2013 Section: Laboratory Last Reviewed
More informationReal-time elastography as a noninvasive assessment of liver fibrosis in chronic hepatitis C Egyptian patients: a prospective study
ORIGINAL ARTICLE Annals of Gastroenterology (2016) 29, 1-5 Real-time elastography as a noninvasive assessment of liver fibrosis in chronic hepatitis C Egyptian patients: a prospective study Lamiaa Mobarak
More informationManagement of Liver Diseases: A Nonhepatologist s Viewpoint
Management of Liver Diseases: A Nonhepatologist s Viewpoint Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,
More informationPreliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity
Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity Dr. Katsutoshi Sugimoto Department of Gastroenterology and Hepatology, Tokyo Medical University, Japan Introduction
More informationNovel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Alina M. Allen, Meng Yin, Sudhakar K. Venkatesh, Taofic Mounajjed, Todd A. Kellogg,
More informationRisk stratification in PBC
Risk stratification in PBC Christophe Corpechot Reference Center for Inflammatory Biliary Diseases Saint-Antoine hospital, Paris, France What is currently known (background) PBC : chronic, progressive
More informationPretreatment Evaluation
Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University
More informationWhen to Treat: Staging Liver Disease David L. Thomas, MD, MPH
When to Treat: Staging Liver Disease David L. Thomas, MD, MPH Professor of Medicine Johns Hopkins School of Medicine Disclosures Received royalties from UpToDate, Inc. Staging refers to the assessment
More informationNon-invasive diagnosis of hepatitis B virus-related cirrhosis
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v20.i2.445 World J Gastroenterol 2014 January 14; 20(2): 445-459 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2014
More informationHEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS
HEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS Essam A. Wahab*, Talaat Fathy** Sameh Saber*** and Hanan S. Ahmad**** Internal Medicine*,
More informationFollow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures
More informationImproved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning
Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning Presenter: Hersh Sagreiya 1, M.D. Authors: Alireza Akhbardeh 1, Ph.D., Isabelle Durot 1, M.D., Carlo Filice 2,
More informationNAFLD and NASH: The Not-So-New Kids on the Block
NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: None Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Description Noninvasive techniques
More informationManagement of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER
Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPMN.180
Clinical Policy: (Daklinza) Reference Number: ERX.SPMN.180 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationNew HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:
New HCV reimbursement criteria 01-2018 Chronic hepatitis C with F2 fibrosis stage Chronic hepatitis C regardless of fibrosis stage if: HIV-HCV coinfection HBV-HCV coinfection Listed for or post-solid organ
More informationClinical Policy: Dasabuvir/ombitasvir/paritaprevir/ritonavir (Viekira XR, Viekira Pak) Reference Number: ERX.SPMN.178
Clinical Policy: (Viekira XR, Viekira Pak) Reference Number: ERX.SPMN.178 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy
More informationNON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES
Best of EASL -, Ethiopia 29 Sep to 01 Oct, 2016 Inaugural meeting of the Sub Saharan GI-Hepatology Working Group Incorporating Best of AGA and Best of EASL NON INVASIVE EVALUATION OF DISEASE PROGRESSION
More informationOriginal papers Med Ultrason 2013, Vol. 15, no. 2, Ioan Sporea, Iulia Raţiu, Simona Bota, Roxana Şirli, Ana Jurchiş
Original papers Med Ultrason 2013, Vol. 15, no. 2, 111-115 DOI: 10.11152/mu.2013.2066.152.is1ir2 Are different cut-off values of liver stiffness assessed by Transient Elastography according to the etiology
More informationAmerican Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis
American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis Joseph K. Lim, 1 Steven L. Flamm, 2 Siddharth Singh, 3 Yngve T. Falck-Ytter,
More informationMonitoring Hepatitis C
Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationA practical clinical approach to liver fibrosis
Singapore Med J 2018; 59(12): 628-633 https://doi.org/10.11622/smedj.2018145 CMEArticle A practical clinical approach to liver fibrosis Rahul Kumar 1, MBBS, MRCP, Eng Kiong Teo 1, MBBS MRCP, How Choon
More informationSection: Laboratory Last Reviewed Date: May Policy No: 47 Effective Date: August 1, 2014
Medical Policy Manual Topic: Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Date of Origin: June 2013 Section: Laboratory Last Reviewed
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationRSNA-QIBA SWS Profile What the Clinical Workflow Would look like and a Review of Biological Confounders. Manish Dhyani, MD Anthony Samir, MD MPH
RSNA-QIBA SWS Profile What the Clinical Workflow Would look like and a Review of Biological Confounders Manish Dhyani, MD Anthony Samir, MD MPH Background Liver fibrosis is the final common pathway for
More informationClinical Policy: Elbasvir/grazoprevir (Zepatier) Reference Number: ERX.SPMN.181
Clinical Policy: (Zepatier) Reference Number: ERX.SPMN.181 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationLength of Authorization: 8-12 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationNew HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:
New HCV reimbursement criteria 01-2018 Chronic hepatitis C with F2 fibrosis stage Chronic hepatitis C regardless of fibrosis stage if: HIV-HCV coinfection HBV-HCV coinfection Listed for or post-solid organ
More informationMaitines septiembre de 2011 Francisco Jorquera Plaza
Bringing Into Focus: A Practical Guide to Using Virologic and Serologic Tests in the Management of Hepatitis B Maitines septiembre de 2011 Francisco Jorquera Plaza 2.000 millones de personas infectadas
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate
More informationPractical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review
Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review Authors: Jennifer Gallacher, 1 *Stuart McPherson 1,2 1. Liver Unit, Newcastle Upon Tyne Hospitals NHS Trust, Freeman
More informationThe Liver for the Nonhepatologist
The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Hepatology Director and Medical Director of Liver Transplantation Intermountain Medical Center Salt Lake City, Utah FORMATTED: 05-14-15
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate
More informationNew HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:
New HCV reimbursement criteria 01-2017 Chronic hepatitis C with F2 fibrosis stage Chronic hepatitis C regardless of fibrosis stage if: HIV-HCV coinfection HBV-HCV coinfection Listed for or post-solid organ
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationPopulations Interventions Comparators Outcomes Individuals: With chronic liver disease. Comparators of interest. are: Liver biopsy
Noninvasive Techniques for the Evaluation and Monitoring of (20441) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization No Review Dates: 01/17, 01/18 Preauthorization is not
More informationPOWERED BY. Innovation in liver disease management
POWERED BY VCTE Innovation in liver disease management An intelligent solution to aid clinical diagnosis, FibroScan uses state of the art fibrosis and steatosis quantification with the most advanced non-invasive
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Harris R, Harman DJ, Card TR, Aithal GP, Guha
More informationJPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print
JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print DOI : 10.1097/MPG.0000000000000489 Points to be considered when Applying FibroScan S Probe for Children with Biliary Atresia
More informationNASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014
NASH : Diagnosis and investigation VII Workshop international, Curitiba, Brazil 29/08/2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France Usual diagnostic circumstances
More informationComparative study between two point Shear Wave Elastographic. Acoustic Radiation Force Impulse (ARFI) elastography
Original papers Med Ultrason 2014, Vol. 16, no. 4, 309-314 DOI: Comparative study between two point Shear Wave Elastographic techniques: Acoustic Radiation Force Impulse (ARFI) elastography and ElastPQ
More informationMedical Review Approaches to the Diagnosis of Liver Fibrosis
Medical Review Approaches to the Diagnosis of Liver Fibrosis Hiroko Iijima Department of Hepatobiliary and Pancreatic Disease Ultrasound Imaging Center, Hyogo College of Medicine Hiroko Iijima Department
More informationLOGIQ S8 XDclear 2.0 Liver Procedures
LOGIQ S8 XDclear 2.0 Liver Procedures See & quantify liver disease in a single exam Clinical Challenge Liver disease affects millions of people worldwide, and the number is growing. Clinicians need a cost-effective,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Ribavirin () Reference Number: CP.HNMC.252 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy
More informationWHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT
WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated
More informationLiver Disease Assessment Among PWID: The Role of Transient Elastography
Liver Disease Assessment Among PWID: The Role of Transient Elastography Peer Brehm Christensen, Professor Department of Infectious Diseases Odense University Hospital Denmark Peer.christensen@dadlnet.dk
More informationClinical cases: HIV/HCV coinfection
Clinical cases: HIV/HCV coinfection José Vicente Fernández-Montero Hospital Carlos III, Madrid Case #1 General considerations about antiviral therapy CASE # 1 43 year-old, male patient Former IDU No prior
More information